Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% - Investors | Eli Lilly and Company


12/4/2024

Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%  Investors | Eli Lilly and CompanyZepbound results in more weight loss than Wegovy in trial, Eli Lilly says  NBC NewsEli Lilly Zepbound More Effective Than Novo’s Wegovy, Study Finds. Lilly Stock Gains.  Barron'sEli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial  CNBCZepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says  CNN...

Original

Tags: company | investors | loss | results | stock | study | trial | wegovy



Let us know what you think!

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Leave a Comment

Scroll back to top